Meeting
2023 ASCO Annual Meeting
A phase I/II study to evaluate the safety, pharmacodynamics, and efficacy of entinostat in combination with atezolizumab and bevacizumab in patients with renal cell carcinoma.
Authors
Roberto Pili
University at Buffalo, Buffalo, NY
Roberto Pili , Naomi B. Haas , Paul Monk III, Theodore F. Logan , Vivek Narayan , Heather Burney , Nabil Adra
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT03024437
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4526)
DOI
10.1200/JCO.2023.41.16_suppl.4526
Abstract #
4526
Poster Bd #
18
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase II study to evaluate the safety, pharmacodynamics and efficacy of entinostat in combination with nivolumab plus ipilimumab in patients with renal cell carcinoma previously treated with nivolumab plus ipilimumab or nivolumab alone.
First Author: Roberto Pili
Poster
2020 ASCO Virtual Scientific Program
Immunomodulation by HDAC inhibition: Results from a phase I study with entinostat in combination with atezolizumab and bevacizumab in metastatic renal cell carcinoma patients.
First Author: Roberto Pili
Poster
2011 ASCO Annual Meeting
Final phase II safety and efficacy results of study MC0452: Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma.
First Author: J. R. Merchan
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase II study of atezolizumab and bevacizumab combination therapy for patients with advanced hepatocellular carcinoma who previously received systemic treatment.
First Author: Takeshi Terashima